

Review of TA396; Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma

Decision

The guidance remains relevant and an update is not needed.

Background

TA396 was published in June 2016 (see appendix A) and scheduled to be considered for review in 2019.

Stakeholders were asked whether the guidance is still relevant and whether there is new evidence that would affect the recommendations (see appendix B).

Based on the information received, we found nothing new that affects the existing recommendations. The guidance remains relevant and an update is not needed.

This may change if NICE becomes aware of new evidence that would make it reconsider.

Decision paper sign off

Jennifer Prescott – Programme Director, Planning and Operations

20 May 2020

Contributors to this paper

Project manager: Charlotte Downing

Appendix A – Information from existing guidance

Original remit

To appraise the clinical and cost effectiveness of dabrafenib and trametinib within their licensed indications for treating advanced unresectable or metastatic BRAF V600 mutation-positive melanoma.

Current guidance

1.1 Trametinib in combination with dabrafenib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation only when the company provides trametinib and dabrafenib with the discounts agreed in the patient access schemes.

Appendix B – Stakeholders asked to comment

Stakeholders who agree that the guidance should remain unchanged

- Melanoma Focus
- Novartis Pharmaceuticals Ltd
- Roche Products Ltd

No response received from

- Association of Cancer Physicians
- Black Health Agency
- British Association of Dermatologists
- British Association of Skin Cancer Specialist Nurses
- British Dermatological Nursing Group
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- British Skin Foundation
- British Society for Dermatological Surgery
- Cancer 52
- Cancer Black Care
- Cancer Equality
- Cancer Research UK
- Cochrane Skin Group
- Department of Health and Social Care
- Genomics England
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Institute of Cancer Research
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie

- Melanoma UK
- MRC Clinical Trials Unit
- Muslim Council of Britain
- National Cancer Research Network
- National Institute for Health Research
- NHS Confederation
- NHS England and NHS Improvement
- NHS Nottingham North & East CCG
- NHS Salford CCG
- OcuMel UK
- Primary Care Dermatology Society
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Scottish Medicines Consortium
- Skcin - Karen Clifford Skin Cancer Charity
- Skin Cancer Research Fund
- Skin Treatment & Research Trust
- Society and College of Radiographers
- South Asian Health Foundation
- Specialised Healthcare Alliance
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Welsh Government
- Welsh Health Specialised Services Committee